Research programme: cancer immunotherapies - Incysus

Drug Profile

Research programme: cancer immunotherapies - Incysus

Latest Information Update: 20 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Incysus
  • Class Antineoplastics; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants; Lymphocyte replacements; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Glioblastoma; Haematological malignancies; Solid tumours

Most Recent Events

  • 21 Mar 2018 Preclinical trials in Glioblastoma in USA (Parenteral), prior to March 2018
  • 20 Mar 2018 Incysus plans a phase I trial for Solid tumours (Combination therapy) in 2018
  • 20 Mar 2018 Pharmacodynamics data from a preclinical trial in Glioblastoma multiforme released by University of Alabama at Birmingham
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top